Amendments to the Claims:

The present listing of the claims replaces all past listings of the claims:

Listing of claims:

1. (Previously Presented) Pharmaceutical preparation, comprising at least one salt whose cationic component contains at least one representative from the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicyline, oxytetracycline and rolitetracycline and whose anionic component contains at least one representative from the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate.

2. (Previously Presented) Pharmaceutical preparation pursuant to claim 1, comprising at least one salt of gentamicin-ibuprofen, gentamicin-naproxen, gentamicin-indomethacin, gentamicin-dexamethasone-21-phosphate, gentamicin-triamcinolone-21-phosphate, tetracycline-indomethacin, tetracycline-indomethacin, neomycin-indomethacin, clindamycin-indomethacin, streptomycin-naproxen, tetracycline-naproxen, clindamycin-naproxen, or streptomycin-ibuprofen.

3. (Previously Presented) Pharmaceutical preparation pursuant to claim 1, which is in the form of at least one member selected from the group consisting of molded bodies, tablets, powders, granules, fibers, knitted fabrics and fleece.

4. (Previously Presented) Pharmaceutical preparation pursuant to claim 1, which is part of a coating applied onto at least one member selected from the group consisting of molded bodies, powders, granules, fibers, knitted fabrics and fleece.

5. (Previously Presented) Pharmaceutical preparation, comprising a mixture in a solid state of aggregation, which mixture is composed of at least one easily

water soluble salt of at least one of gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicycline, oxytetracycline and/or rolitetracycline and at least one easily water soluble salt of at least one of ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and/or triamcinolone-21-sulfate and at least one inorganic and/or organic pharmaceutical adjuvant, and said pharmaceutical preparation has a shape of tablets and/or molded bodies.

6. (Previously Presented) Method for producing a pharmaceutical preparation pursuant to claim 3, comprising forming hardly water soluble antiphlogistic antibiotics salts, wherein said salts form controlled-release antiphlogistic/antiphlogistics-antibiotic/antibiotics drugs.

7. (Previously Presented) Method for producing a pharmaceutical preparation pursuant to claim 5, comprising forming hardly water soluble antiphlogistic antibiotics salts, wherein said salts form controlled-release antiphlogistic/antiphlogistics-antibiotic/antibiotics drugs.

8. (Previously Presented) A method of treating a bacterial infection in a patient comprising administering a pharmaceutical preparation pursuant to claim 1 to said patient as a controlled-release antibiotics drug.

9. (Previously Presented) A permanent or temporary implant comprising the pharmaceutical preparation pursuant to claim 3.

10. (Previously Presented) A permanent or temporary implant comprising the pharmaceutical preparation pursuant to claim 5.

11. (Previously Presented) A method for producing a pharmaceutical preparation according to claim 6, wherein said hardly water soluble antiphlogistic antibiotics salts are in tablet and/or molded body form.

12. (Previously Presented) A method for producing a pharmaceutical preparation according to claim 7, wherein said hardly water soluble antiphlogistic antibiotics salts are in tablet and/or molded body form.

13. (New) The method according to claim 6, wherein said forming comprises precipitating antipholgistic antibiotics salts.

14. (New) The method according to claim 7, wherein said forming comprises precipitating antipholgistic antibiotics salts.